Predictive Oncology Inc. (POAI) News
Filter POAI News Items
POAI News Results
|Loading, please wait...|
POAI News Highlights
- POAI's 30 day story count now stands at 5.
- Over the past 23 days, the trend for POAI's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about POAI are DRUG.
Latest POAI News From Around the Web
Below are the latest news stories about Predictive Oncology Inc that investors may wish to consider to help them evaluate POAI as an investment opportunity.
A Quick Glance At Predictive Oncology Inc. (NASDAQ: POAI) Stock: It Is up 1.37% From Its 52-Week Low; YTD, It Is Down -23.07 Percent
During the last session, Predictive Oncology Inc. (NASDAQ:POAI)s traded shares were 0.27 million, with the beta value of the company hitting 1.46. At the end of the trading day, the stocks price was $0.73, reflecting an intraday loss of -2.36% or -$0.02. The 52-week high for the POAI share is $2.20, that puts it down A Quick Glance At Predictive Oncology Inc. (NASDAQ: POAI) Stock: It Is up 1.37% From Its 52-Week Low; YTD, It Is Down -23.07 Percent Read More »
MINNEAPOLIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI ) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that POAI expects will grow to $20 billion in the next three years, reported the Company today in outlining its strategy for 2022. The Company plans to leverage its existing pharma relationships to market PeDAL™ in a move that will take the proprietary platform out of the research lab into the pipelines of oncology drug discovery companies. POAI recently completed its Discovery 21 evaluation, the proof of concept for PeDAL. CoRE™, POAI''s Artificial Intelligence program, together with tumor profile data, human tumor samples and active machine learning, power PeDAL to determine the most effective drug treatmen...
Predictive Oncology (POAI) said its Helomics subsidiary''s evaluation showed that its Artificial Intelligence (AI) program CoRE (Computational Research Engine), combined with tumor…
MINNEAPOLIS, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary’s evaluation demonstrated their proprietary Artificial Intelligence (AI) program CoRE™ (Computational Research Engine), combined with their tumor profile data and matched ovarian cancer samples, could identify potential new chemotherapy drug uses. These drugs are not currently approved for ovarian canc
Penny stocks under $3 are full of potential and potential pitfalls.
MINNEAPOLIS, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company’s Annual Meeting of Stockholders was convened at 3:00 p.m. Central Time on December 23, 2021 and was immediately adjourned due to lack of the required quorum. A quorum was not achieved because there were fewer than a majority of outstanding shares entitled to v
Zacks Investment Research upgraded shares of Predictive Oncology (NASDAQ:POAI) from a hold rating to a buy rating in a report published on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $1.00 price objective on the medical instruments suppliers stock. According to Zacks, Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine  The post Predictive Oncology (NASDAQ:POAI) Upgraded to Buy at Zacks Investment Research appeared first on ETF Daily News .
Predictive Oncology Inc. (POAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
EAGAN, Minn., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, is moving in the right direction.
Zacks Investment Research lowered shares of Predictive Oncology (NASDAQ:POAI) from a buy rating to a hold rating in a research report sent to investors on Friday, Zacks.com reports. According to Zacks, Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and